Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
PMC/PubMed Indexed Articles

Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer

Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection

Google Scholar citation report
Citations : 1140

Archives in Cancer Research received 1140 citations as per Google Scholar report

Flyer image
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
View More
Share This Page

The role of Topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines-based chemotherapy in locally advanced breast cancer

2nd Edition of International Conference on Clinical Oncology and Molecular Diagnostics
June 11- 13, 2018 Dublin, Ireland

Mohamed M Gamea, Ashraf F Barakat and Fatma Z Hussein

Aswan University Hospital, Egypt Tanta University Hospital, Egypt

Posters & Accepted Abstracts: Arch Cancer Res

Abstract:

Background: Topoisomerase II-α is a molecular target of anthracyclines; several studies have suggested that topoisomerase II-α expression is related to response to anthracycline treatment. The objective of this study was to evaluate if topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients. Material & Methods: This prospective study included 50 patients with primary non metastatic locally advanced breast cancer according to American Joint Committee for cancer staging (T3-4; N0-3) were treated between January 2012 and June 2012 at Clinical Oncology Department, Tanta University Hospital. Topoisomerase II-α, HER2, estrogen receptor (ER), progesterone receptor (PR) expression and KI-67 were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded breast tumors from 50 patients presenting with locally advanced breast cancer.
Results: Tumors from 50 patients, 45 (90%) showed topoisomerase II-α overexpression, 34 (68%) for ER positive, 32 (64%) for PR positive and 10 (20%) for HER2 overexpression and 16 (32%) for high KI-67. Significant correlation was seen between clinical and pathological response with topo IIA, HER2 and KI-67. P value (≤0.001), (0.005) and (0.015) respectively. 1- Responders: Clinical (CR): 3 patients had co-expression of topo II and HER2, hormonal receptor negative and high KI-67. Clinical (PR):43 patients, majority of them had topo IIA overexpression. 2-Non responders: 4(8%) patients all had negative (TOPOII/HER2), low KI-67 and 2 had hormonal receptor positive and another two had hormonal receptor negative. Conclusions: Our data support a correlation between topoisomerase II-α expression in locally advanced breast cancer patients and improved clinical benefit with neoadjuvant anthracyclines based therapy. mohammed.game3@hotmail.com
 

PDF HTML